PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27810232-4 2017 OBJECTIVE: To investigate which subsets of IL-17-producing cells are involved in psoriasis-like skin inflammation in a TPA (tumor promoter 12-O-tetradecanoylphorbol-13-acetate)-induced K14.Stat3C mouse model. Tetradecanoylphorbol Acetate 119-122 keratin 14 Mus musculus 185-188 30905492-4 2019 METHODS: We evaluated the effect of topical S18-000003 on psoriasis-like skin inflammation and influence on the thymus in a 12-O-tetradecanoylphorbol-13-acetate-induced K14.Stat3C mouse psoriasis model. Tetradecanoylphorbol Acetate 124-160 keratin 14 Mus musculus 169-172 27810232-4 2017 OBJECTIVE: To investigate which subsets of IL-17-producing cells are involved in psoriasis-like skin inflammation in a TPA (tumor promoter 12-O-tetradecanoylphorbol-13-acetate)-induced K14.Stat3C mouse model. Tetradecanoylphorbol Acetate 139-175 keratin 14 Mus musculus 185-188 27810232-5 2017 METHOD: Skin-infiltrating cells were isolated from inflamed lesions of TPA-treated K14.Stat3C transgenic mice, and analyzed for IL-17 producing cell subsets by flow cytometry. Tetradecanoylphorbol Acetate 71-74 keratin 14 Mus musculus 83-86 27810232-6 2017 RESULTS: We observed significantly increased numbers of IL-17-producing CD4+ T cells, CD8+ T cells and dermal gammadelta T cells in TPA-induced skin lesions of K14.Stat3C mice. Tetradecanoylphorbol Acetate 132-135 keratin 14 Mus musculus 160-163 27810232-11 2017 CONCLUSION: In TPA-induced lesional skin of K14.Stat3C mice, IL-17-producing CD4+ Th17 cells, CD8+ Tc17 cells, dermal gammadelta T cells and TCR- cells probably containing ILCs all participated in skin inflammation, which is similar to human clinical psoriatic features. Tetradecanoylphorbol Acetate 15-18 keratin 14 Mus musculus 44-47 19626033-6 2010 Unexpectedly, topical treatment of K14-RIP4 mice with 12-O-tetradecanoylphorbol-13-acetate (TPA) induced dramatic, neutrophilic inflammation, an effect that was independent of tumor necrosis factor type 1 receptor (TNFR1/p55) function. Tetradecanoylphorbol Acetate 54-90 keratin 14 Mus musculus 35-38 19626033-6 2010 Unexpectedly, topical treatment of K14-RIP4 mice with 12-O-tetradecanoylphorbol-13-acetate (TPA) induced dramatic, neutrophilic inflammation, an effect that was independent of tumor necrosis factor type 1 receptor (TNFR1/p55) function. Tetradecanoylphorbol Acetate 92-95 keratin 14 Mus musculus 35-38 16452183-6 2006 On comparison with all previous HK1.ras carcinomas, such TPA-induced carcinomas expressed atypical retention of keratin K1 and lack of K13, a unique marker profile exhibited by TPA-induced K14.cre/PTEN(flx/flx) papillomas that also lacked endogenous c-ras(Ha) activation. Tetradecanoylphorbol Acetate 57-60 keratin 14 Mus musculus 189-192 18579711-0 2008 TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Tetradecanoylphorbol Acetate 0-3 keratin 14 Mus musculus 58-66 18579711-5 2008 Inflammation was induced in the ear skin with five topical applications of 12-O-tetradecanoyl phorbol-13-acetate (TPA) and a significantly increased inflammation was found in TPA-induced K14/VEGF transgenic animals compared with wild-type mice. Tetradecanoylphorbol Acetate 175-178 keratin 14 Mus musculus 187-190 18579711-11 2008 In conclusion, the TPA-induced phenotype in K14/VEGF animals displayed several features of psoriasis, including a T(h)17 cytokine profile and a chronic-like progression, and can be used as an in vivo screening model of psoriasis. Tetradecanoylphorbol Acetate 19-22 keratin 14 Mus musculus 44-47 17583568-4 2007 62: 2516, 2002) that these mice, referred to as keratin 14 (K14).COX2 mice, were unexpectedly very resistant to 12-O-tetradecanoylphorbol 13-acetate (TPA) tumor promotion. Tetradecanoylphorbol Acetate 112-148 keratin 14 Mus musculus 48-58 17583568-4 2007 62: 2516, 2002) that these mice, referred to as keratin 14 (K14).COX2 mice, were unexpectedly very resistant to 12-O-tetradecanoylphorbol 13-acetate (TPA) tumor promotion. Tetradecanoylphorbol Acetate 112-148 keratin 14 Mus musculus 60-63 17583568-4 2007 62: 2516, 2002) that these mice, referred to as keratin 14 (K14).COX2 mice, were unexpectedly very resistant to 12-O-tetradecanoylphorbol 13-acetate (TPA) tumor promotion. Tetradecanoylphorbol Acetate 150-153 keratin 14 Mus musculus 48-58 17583568-4 2007 62: 2516, 2002) that these mice, referred to as keratin 14 (K14).COX2 mice, were unexpectedly very resistant to 12-O-tetradecanoylphorbol 13-acetate (TPA) tumor promotion. Tetradecanoylphorbol Acetate 150-153 keratin 14 Mus musculus 60-63 16452183-6 2006 On comparison with all previous HK1.ras carcinomas, such TPA-induced carcinomas expressed atypical retention of keratin K1 and lack of K13, a unique marker profile exhibited by TPA-induced K14.cre/PTEN(flx/flx) papillomas that also lacked endogenous c-ras(Ha) activation. Tetradecanoylphorbol Acetate 177-180 keratin 14 Mus musculus 189-192 16024603-5 2005 In response to the 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) mouse skin carcinogenesis protocol, K14-Pdcd4 mice showed significant reductions in papilloma formation, carcinoma incidence, and papilloma-to-carcinoma conversion frequency compared with wild-type mice. Tetradecanoylphorbol Acetate 57-93 keratin 14 Mus musculus 136-139 12566297-8 2003 Again, DMBA/PMA-induced tumor formation was less (71% versus 89%) and significantly delayed (P = 0.02) in K14-survivin p53+/- animals compared with p53+/- non-Tgs. Tetradecanoylphorbol Acetate 12-15 keratin 14 Mus musculus 106-109 12759452-3 2003 Strikingly, the K14/IL-1 alpha mice were completely resistant to papilloma and carcinoma formation induced by a two-stage DMBA/TPA protocol, while littermate controls developed both tumor types. Tetradecanoylphorbol Acetate 127-130 keratin 14 Mus musculus 16-19